MLYS ▼ -7.2% - Mineralys Therapeutics, Inc. $MLYS - Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026 Mineralys Therapeutics shares fell 7.2% today despite the company's announcement that Transform-HTN Open-Label Extension trial data has been selected for late-breaking presentation at the American Heart Association Scientific Sessions 2026. The decline suggests investors may have interpreted the timing of the presentation—scheduled for next year rather than imminent—as insufficient near-term catalyst or preferred to see data released immediately rather than wait for the conference. 23-SEP-2026 04:05 PM ET